RxDoctor Payments Data

Patricia Mbola

Gerontology · Houston, TXNPI 1962693523

Payments from drug & device makers

$3,429in general payments, 2019–2025

Across 92 payments — averaging $37.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$1K
  • Neurocrine Biosciences, Inc.$723
  • Otsuka America Pharmaceutical, Inc.$441
  • Teva Pharmaceuticals USA, Inc.$414
  • Axsome Therapeutics, Inc.$138
  • Alkermes, Inc.$125
  • plus $275 from 3 others

What the payments were for

  • Food & beverage$3,39299%
  • Education$371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,429 in reported general payments places this provider in the 85th percentile of 653 gerontology providers in Texas.

See all gerontology providers in Texas

Medicare billing

Part B allowed, 2024
$240,106
Medicare patients
455
Services billed
2,814

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate115$468,507
Austedo XrDeutetrabenazine42$201,115
Clozapine OdtClozapine17$5,885
Divalproex Sodium128$3,245
Duloxetine Hcl106$2,837
Mirtazapine161$2,815
Memantine Hcl103$2,574
Sertraline Hcl115$2,334
Trazodone Hcl192$2,233
Quetiapine Fumarate107$1,986
Escitalopram Oxalate146$1,583
Hydroxyzine Hcl69$1,544
Buspirone Hcl98$1,375
Lorazepam120$1,345
Donepezil Hcl103$1,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$723$468,507115 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$414$201,11542 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 653 gerontology providers in Texas.

Other gerontology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →